Swiss experts have abandoned the over 100 year old tuberculin skin test favoring the use of interferon-a release assays such as QuantiFERON-TB Gold for screening patients for tuberculosis infection prior to initiating biological treatments (such as anti-tumor necrosis factor-a therapy). QFT is being comercialized by Australian biotechnology group Cellestis International.
In recommendations published in the current issue of the Swiss Medical Weekly, experts advocate the use of QFT in place of the TST, as it is more accurate (sensitive and specific) than the TST in individuals with immune suppression and provides rapid and reproducible results. These recommendations come after the recent approval of the In-Tube format of QFT by the US Food and Drug Administration and its widespread use in Europe and Asia for a number of years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze